Pular para o conteúdo principal
Ranking Invest

GNFT - Genfit S.A.

Segmento: HealthcareGenfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Análise Ranking Invest

Valuation estimado
-$ 14.95 Mi
Último Balanço Atualizado: 2T2024

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 97.36 Mi

Dívida Líquida

$ 6.16 Mi

L4T

$ 37.43 Mi

MM4T

13.04%

Indicadores Básicos

ROE

38.44%

Índices de Previsibilidade

Faturamento

G1.03

Lucro

F2.59

Margem

F5.28

Índices de Tendência

Faturamento

C3.46

Lucro

B5.77

Margem

D0.01

Índices de Endividamento

DIV/PAT

0.06

DIV/L4T

0.16

Dívidas
Cotação
Gráfico Lucro/Faturamento X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.